No published license or data use terms

Datasets under this license

• Asan Medical Center SWI Microbleed Set (ARIA-H)

  In-house set of 565 SWI brain MRI scans from Asan Medical Center, Seoul (429 with microbleeds), labelled by one neuroradiologist to train microbleed detection for ARIA-H severity grading. Described in a 2025 AAIC abstract; not publicly released.

• AURORA (Leiden D-CAA cohort)

  Prospective Leiden cohort of 120 presymptomatic and symptomatic carriers of Dutch-type hereditary cerebral amyloid angiopathy with yearly 3 T and 7 T brain MRI (SWI, FLAIR, T2w), CSF and cognitive tests. Data on request from the authors.

• Brain Before Stroke (BBS)

  Prospective cohort of 428 adults with a first-ever supratentorial ischemic stroke at Bordeaux University Hospital, imaged on 3 T GE MRI 24 to 72 hours after onset (DWI, FLAIR, T1, SWAN, T2*-GRE) with 1-year outcomes. Shared on request to the PI.

• Cao 2026 In-house cSS Test Set

  In-house test set of 10 patients with confirmed cortical superficial siderosis on SWI or T2*-weighted MRI, with manual lesion delineations validated by a neuroradiologist. Used to evaluate synthetic-data training for cSS segmentation; not released.

• Clarity AD (lecanemab phase 3 trial imaging)

  Serial safety MRI at 1.5 T or 3 T (3D T1w, FLAIR, T2*-GRE, T2w, DWI) of 1795 people with early Alzheimer disease in the Eisai and Biogen lecanemab phase 3 trial, centrally read for ARIA. The images are not shared; the safety paper states its data are not available.

• CMUH SWAN Microbleed Set

  205 clinical GE SWAN brain MRI exams from China Medical University Hospital, Taiwan (104 with microbleeds, 101 without), with voxel-wise microbleed masks by one neurologist. Used for synthetic-to-real microbleed segmentation; shared only through research collaboration.

• EMERGE and ENGAGE (aducanumab phase 3 trial imaging)

  Serial safety MRI at 1.5 T or 3 T (FLAIR for ARIA-E, T2*-GRE for ARIA-H) of 3285 people with early Alzheimer disease in Biogen's two aducanumab phase 3 trials, with amyloid PET in a substudy. The images are not shared; Biogen does not generally share imaging data.

• FOCAS (Leiden sporadic CAA cohort)

  Prospective Leiden cohort of 126 participants with sporadic cerebral amyloid angiopathy seen at yearly research visits with 3 T SWI brain MRI, 7 T MRI, CSF and clinical follow-up, including semi-automatic siderosis masks for a small subset. Data on request from the authors.

• LINCHPIN CT and pathology set (CT images)

  Admission non-contrast head CT of 110 adults with first-ever intracerebral haemorrhage in Lothian, Scotland, who died and had a research autopsy, with masked CT ratings, APOE genotype and CAA grading. The ratings are open; the CT images are not shared.

• MGH CAA cohort, cSS evolution set

  Baseline and follow-up 1.5 T MRI with T2*-GRE or SWI of 118 patients with probable CAA without intracerebral haemorrhage from Massachusetts General Hospital (2000-2015), with visual ratings of siderosis progression and new microbleeds. Not publicly shared.

• OXVASC T2*-GRE Microbleed Set

  3 T 2D T2*-weighted GRE brain MRI of 74 Oxford Vascular Study patients after minor stroke or TIA, with manual voxel segmentations of 366 cerebral microbleeds in the 36 patients who had them. Shared on request to the OXVASC PI.

• Radboudumc TBI SWI Microbleed Set

  Single-centre 3 T SWI and T1 MRI from Radboudumc, Nijmegen: 81 studies of 45 patients with moderate to severe traumatic brain injury and 18 healthy controls, with microbleed segmentations and six-observer point annotations. Not publicly released.

• SHIVA cohort

  Ongoing French cohort of adults over 60 with extensive or minimal white matter hyperintensities, built to find imaging and circulating biomarkers of cerebral small vessel disease. 150 enrolled by March 2024, 3 T Siemens Prisma MRI with T2*-GRE and optional SWI. Not public.

• TICH-2 MRI Sub-study

  Multicentre brain MRI (DWI, FLAIR, T2*-GRE, T1w, T2w, optional SWI) of 219 patients with acute spontaneous intracerebral haemorrhage in the TICH-2 tranexamic acid trial, with microbleed masks in a labelled subset of 115 SWI scans. Shared on written request to the sub-study PI.

• TRAILBLAZER-ALZ 2 (donanemab phase 3 trial imaging)

  Serial safety MRI (FLAIR for ARIA-E, T2*-GRE for ARIA-H), volumetric MRI and amyloid and tau PET of 1736 people with early symptomatic Alzheimer disease in Lilly's donanemab phase 3 trial. The images are not shared; Lilly generally excludes MRI scans from its Vivli data sharing.

• UCSF Radiation-Induced Microbleed 7 T SWI Set

  91 7 T SWI scans of 73 glioma patients with radiation-induced cerebral microbleeds at UCSF, with 2,835 true microbleeds labelled among detector candidates. Described in a 2019 paper; no data release or sharing route.

• WRAP

  Longitudinal US cohort enrolled at midlife and enriched for a parental history of Alzheimer's disease, with cognition every two years and MRI (T1, T2, FLAIR), amyloid PET (PiB, NAV4694) and MK-6240 tau PET in subsets. Access by application to the WRAP committee.

• Yonsei/Gachon SWI Microbleed Dataset

  3 T SWI, phase and magnitude brain MRI of 179 subjects from Gachon University Gil Medical Center with point labels for 760 cerebral microbleeds. Offered with the 2020 paper, but the authors withdrew the data in 2021.